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ABSTRACT 
Skeletal muscle is a highly plastic tissue; it has a great capacity to adapt to 
environmental demands throughout life. The structural and functional changes that 
occur in response to exercise training are well characterized whereas much less is 
known about these adaptive processes at the cellular and molecular levels. A possibly 
underestimated aspect of skeletal muscle adaptation to exercise is the remodeling of the 
extracellular matrix (ECM). Degradation and processing of the extracellular matrix are 
carried out by a specific category of proteases, especially the matrix metalloproteinase 
family (MMPs). Such remodeling is of crucial importance for successful extravasation 
of circulating cells and for the migration of cells between the compartments of the 
tissue. Furthermore, degradation products of ECM components are not always mere 
debris; several fragments of structural proteins have biological activity after proteolytic 
processing, and MMP activity may also release growth factors stored in the ECM. 
Little is known about these enzymes in skeletal muscle of humans and how 
physiological stimuli such as exercise and exercise training affect their expression and 
activity. 
Therefore, the aim of this thesis was to characterize: 1. skeletal muscle MMP activation 
in response to a single bout of exercise and exercise training with regard to gene 
expression and enzyme activity, 2. exchange of factors associated with MMP activity 
between exercising leg and the circulation during exercise, 3. possible cellular sources 
of MMP in skeletal muscle tissue and blood, 4. the effects of restricted leg blood flow, 
and thereby reduced oxygen delivery, to the exercising leg on skeletal muscle and 
circulating levels of MMP and 5. the effects of the myokine interleukin-6 on MMP 
levels in skeletal muscle and in the circulation.  
MMP-9 is activated and transcriptionally upregulated in human skeletal muscle after a 
single bout of exercise. In contrast, MMP-2 is activated and transcriptionally 
upregulated in human skeletal muscle by exercise training but not after a single bout of 
exercise. Factors possibly linked to proteolytic processing of MMP-9, such as collagen 
IV and VEGF-A, are released from the leg to the circulation during a single bout of 
exercise in humans. Circulating levels of MMP-9 increase during and after a single 
bout of exercise in humans but do not seem to originate from the skeletal muscle. The 
myokine interleukin-6 induces an increase in circulating MMP-9 in parity with what is 
seen after a single bout of exercise in humans, interleukin-6 also induces gene-
expression and release of MMP-9 from the human moncyte cell-line THP-1, but not 
from human myoblasts, myotubes or endothelial cells indicating that monocytes could 
be the source of the interleukin-6 induced increase in circulating MMP-9.  
The results from this thesis show that both MMP-2 and MMP-9 are expressed in 
skeletal muscle and upregulated by a physiological stimulus such as exercise but 
probably through different mechanisms. Furthermore, it indicates that remodeling of 
extracellular matrix and release of growth factors in the skeletal muscle occur after only 
a few minutes of exercise. Overall, the results support MMPs to play a role in the 
adaptation of the skeletal muscle to physical activity in humans. 
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1 BACKGROUND 
1.1 SKELETAL MUSCLE STRUCTURE AND FUNCTION 
Skeletal muscle, the largest organ of the human body, has numerous functions, ranging 
from force generation and movement to mechanical protection of underlying soft tissue 
and maintenance of body temperature. The structure of skeletal muscle is well 
characterized. Muscle fibers constitute the main cellular component of muscle. Other 
cell types present in skeletal muscle are endothelial cells, satellite cells, pericytes, 
fibroblasts, macrophages and mast cells. 
Each fiber contains several nuclei because of its embryological development 
pattern. The skeletal muscles of the limbs develop from somites, which migrate to the 
limb buds where they differentiate into spindle-shaped, elongated myoblasts. The first 
evidence of limb musculature is observed during the seventh week of development. 
During elongation of the limbs, muscle fibers develop through proliferation and fusion 
of myoblasts. Contractile myofibrils and their typical cross-striations appear by the end 
of the third month of development (1). In the adult, each muscle fiber is surrounded by 
connective tissue, the endomysium, which loosely interconnects adjacent muscle fibers. 
The endomysium contains mononuclear cells called satellite cells. Both the embryonic 
origin and the functional relevance of these cells have been debated since they were 
first described in 1961, but during the past decade, it was established that satellite cells 
are activated by exercise and muscle damage (2-4). Activated satellite cells proliferate 
and differentiate into new myotubes or new segments of fibers. The endomysium also 
contains capillaries and nerves, which provide the muscle fibers with oxygen and 
nutrients and regulate muscle contraction, respectively. Each muscle fiber is innervated 
by a motor neuron attached to the myofiber at the motor endplate(5). 
Skeletal muscle is divided into a series of compartments called fascicles, each of 
which contains a bundle of muscle fibers. Each fascicle is surrounded by a perimysium, 
which contains the larger branches of blood vessels and nerves. The entire muscle is 
surrounded by the epimysium, which separates it from other tissues and organs. The 
extracellular matrix (ECM) helps to form the architecture of skeletal muscle and is a 
support system for nerves and blood vessels (5, 6). 
Different muscle fiber classification systems have been established based on 
either functional or biochemical oxidative properties of muscle fibers. The most 
common system used for humans involves classification of fibers as type I or type II. 
Initially, classification was achieved using histochemical staining of ATPase, an 
enzyme responsible for ATP cleavage and energy release in the contractile process and 
related to the speed of contration (7). Various muscle fibers express different amount 
and isoforms of ATPase, which relate to the maximal contraction velocity of the fiber. 
Later the expression of myosin heavy chain (MHC) isoforms has been used as 
classifiers of fiber type. MHC type I fibers are characterized by slow-contractile 
velocity and MHC type II by fast-contractile velocity. Type II fibers can be further 
divided into type IIA and IIB/IIX (8, 9). There is a good agreement between the 
ATPase and the MHC classifications systems. The fiber types also differ in respect of 
oxidative and glycolytic capacity and the density of mitochondria and capillaries. Type 
I fibers are more oxidative and fatigue resistant than type II fibers, whereas the latter 
are more glycolytic and are more sensitive to fatigue than the former (10, 11). Despite 
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the association between the contractile and metabolic characteristics of muscle fibers, 
changes in their contractile and metabolic properties may occur independently of one 
another under circumstances such as adaptation to exercise training. These studies have 
reported unaltered contractile properties with exercise training but an increase in the 
oxidative capacity of muscle fibers after exercise training (12-14). This clearly suggests 
that different regulatory pathways underlie the contractile and biochemical properties 
of muscle fibers.  
 
1.2 SKELETAL MUSCLE PLASTICITY 
The skeletal muscle is a highly plastic organ; it has a great capacity to adapt to 
environmental demands, even in the adult. The structural and functional changes that 
occur in response to exercise training are well characterized. Most of these changes are 
related to processes in the actual muscle fiber and include altered contractile properties 
and increased mitochondrial density, reflected in an increase in levels of mitochondrial 
enzymes and oxidative enzymes of the citric acid cycle, elevated cytochrome and 
respiratory chain activity and increased fatty acid beta-oxidation (15, 16). Even though 
the plasticity of skeletal muscle fibers is best characterized, other cell types are 
involved in the adaptive processes of muscle. For example, changes in capillarization 
after exercise training involve the activation, migration and proliferation of endothelial 
cells (17-19). During the past decade, the importance of both circulating and resident 
progenitor cells as well as other cell types located in skeletal muscle tissue has been 
recognized in respect of their participation in skeletal muscle remodeling (20). The 
main resident stem-cell in the skeletal muscle is the satellite cell. It is generally 
assumed that 3–8% of the cell nuclei in the skeletal muscle tissue of healthy adult 
humans is of SaC origin (2). It is assumed that SaCs are activated by muscle injury, 
after which they proliferate and differentiate into muscle fibers (21, 22). Animal studies 
have suggested that, in addition to SaCs, pluripotent circulating hematopoietic cells and 
resident pericytes are involved in the adaptive processes of skeletal muscle (23). It has 
been suggested that these cells participate in angiogenesis and affect skeletal muscle 
fibers via paracrine signaling (24, 25). 
In the context of exercise and exercise training, the degree of adaptive response 
is related to the duration, intensity and frequency of the exercise bouts, albeit with very 
large interindividual variation (26-28). Exercise performance, and ultimately adaptation 
to exercise, depends on the contraction of the muscle fiber (29). A muscle contraction 
is induced through the release of acetylcholine from the motor neuron, which activates 
nicotinic acetylcholine receptorsin the myofiber. Calcium is released from the SR into 
cytoplasm of the muscle fiber and interacts with troponin, enabling myosin to interact 
with the actin skeleton of the myofiber. Force develops when a moving part of the 
myosin molecule interacts with actin filaments in the crossbridge cycle, which requires 
ATP. Relaxation occurs when calcium is pumped out of the cytoplasm by an ATP-
dependent calcium pump in the SR membrane (30). Factors altered with muscle 
contraction and shown to influence adaptation to exercise are mechanical stretch, fiber 
recruitment and changes in intracellular levels of ATP, Ca++, O2, glycogen and cAMP 
(16, 31-36). Importantly, skeletal muscle adaptation in response to exercise is probably 
not associated with any one factor but with the integration of multiple stimuli at 
systemic and local levels. Autocrine and paracrine substances, hormones, temperature 
and circulatory factors are likely involved in adaptation to exercise (29, 33, 35). The 
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disturbance in muscle homeostasis differs depending on the type of exercise, which 
results in differences in adaptive responses and, ultimately, a skeletal muscle phenotype 
related to the nature of the exercise being performed (16, 29). 
 
1.2.1 Regulating processes  
Structural and functional changes in skeletal muscle fibers depend on changes in 
protein level or activation, which may be pretranslational, translational, 
posttranslational, or a combination of all three (16, 35). Protein level is a function of the 
balance between the rate of synthesis and the rate of degradation. Increased muscle 
activity is predominantly associated with increased protein synthesis, whereas 
decreased muscle activity causes decreased protein synthesis (31, 33, 35, 37). 
The adaptation of the muscle, as described above, is specific to the nature of the 
exercise stimulus, and different types of exercise activate different signaling pathways 
in the tissue. During the past few decades, transgenic animals in combination with 
traditional animal and human exercise models have provided crucial information on 
possible regulatory pathways and processes underlying skeletal muscle adaptation to 
exercise. With resistance exercise training, fiber hypertrophy is achieved via increased 
synthesis of contractile proteins (38). Compared with endurance exercise, little 
mitochondrial biogenesis and neovascularization has been reported with resistance 
exercise (33, 39). Recent evidence indicates that resistance exercise activates specific 
signal transduction pathways such as Akt and mTOR, which regulate protein synthesis 
and presumably regulate the degree of protein degradation (38, 40). Furthermore, 
activation of satellite cells, with proliferation and differentiation into new myonuclei, 
has been reported to be more associated with resistance exercise than with other 
exercise regimes (39, 40). This provides a larger protein synthesis machinery to 
accommodate the increasing needs of the growing myofibers (38, 40). In contrast, 
endurance exercise activates signal transduction pathways such as AMPK, PGC1 and 
HIF-1, which in turn result in increased expression of mitochondrial and other 
oxidative genes and angiogenic growth factors, ultimately resulting in increased 
capillary density and oxidative capacity (19, 41, 42). In the middle of this spectrum is 
sprint and high-intensity interval exercise. It has been known since the 1970s that such 
exercise training regimens increase both oxidative capacity, strength and muscle mass 
(43). More recent studies have further established that high-intensity interval training 
(HIT) activates signaling of AMPK and p38 MAPK to PGC-1a, which could explain, 
in part, the metabolic adaptations induced by HIT, including mitochondrial biogenesis 
and an increased capacity for glucose and fatty acid oxidation (44). Thus, exercise-
induced skeletal muscle remodeling represents a continuum both in respect of 
functional and structural changes, ranging from those observed after repetitive high-
intensity, short-duration bouts to those observed after low-intensity, long-duration 
bouts. 
A possibly underestimated process in the adaptation to exercise training is 
exercise-induced changes in protein bioavailability. An effect of exercise on growth 
factor bioavailability is evident in observations of an increase in interstitial and 
circulating levels of vascular growth factor A (VEGF-A) after a few minutes’ exercise 
(45, 46). This, in my opinion, must reflect release of preexisting protein rather than 
increased transcription or translation. Protein release from granules or binding protein 
are two possibilities underlying an immediate increase in bioavailable proteins.  
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Another aspect of skeletal muscle plasticity that may be of greater importance 
than is generally appreciated is the proteolytic degradation of the basal lamina and the 
extracellular matrix. The satellite cells (SaC) resides below the basal lamina of the 
skeletal muscle fiber (3, 4). Proliferation, differentiation and fusion with muscle fibers 
(21, 22) seems to be dependent on ECM remodeling as demonstrated by the report in 
which migration of myoblasts after a crush injury required proteolytic processing of the 
ECM (47). Further, in exercise-induced angiogenesis, proteolytic degradation of the 
capillary basal lamina is crucial for angiogenesis (48).  
 
1.3 EXTRACELLULAR MATRIX AND SKELETAL MUSCLE PROTEASE 
FAMILIES 
1.3.1 Extracellular matrix  
The ECM immediately outside the myocyte cell membrane (sarcolemma) is the basal 
lamina. The basal lamina mainly contains type IV collagen, laminins and fibronectin, 
but also contains minor components such as entactin/nidogen-1, perlecan and agrin. 
The collagens are a class of at least 25 different proteins that are localized in the ECM 
(49). 
Collagen molecules have three α chains that form a triple helix (50). Collagens 
types I, II, III, V and XI are termed ‘fibrillar collagens’ because of their capacity to 
form elongated fibers. They are the predominant components of the interstitial stroma 
(51). Collagen types IV, VI, VIII and X do not form fibrils but are cross-linked into a 
three-dimensional network. They are major components of the basal lamina (52, 53). 
Collagens provide mechanical stability and strength by interacting with one another or 
with other ECM components. Gelatin is denatured collagen and is not present under 
physiological circumstances, but is produced when collagen is denatured to gelatin 
under highly acidic conditions or when mammalian collagen is heated to more than 70 
°C (54). Laminin, together with collagen type IV, is one of the main components of the 
basement membrane (55). Laminin is a family of glycoproteins that are composed of α, 
β and γ chains that generate several different isoforms that vary in size, composition 
and structure Laminins are synthesized by a wide variety of cells and appear to have a 
variety of biological functions such as cell adhesion, cell migration and cell 
differentiation (56, 57). Several laminin isoforms are upregulated threefold by 
endurance exercise training for three weeks (58). In animal models of muscle, levels of 
unloading laminins have been shown to be decreased and become degraded in the ECM 
along with collagen IV (59). 
Fibronectin is a multifunctional glycoprotein that is found in two different 
forms: soluble and solid. The soluble form, which is produced by hepatocytes, is found 
in body fluids. The solid form, which is produced by many different cell types, 
including fibroblasts, endothelial cells and others, is found in loose connective tissue 
and most basement membranes (60, 61). Fibronectin acts through several distinct 
domains to promote cell adhesion, cell migration and matrix assembly(60). In skeletal 
muscle, fibronectin is upregulated by endurance exercise and has been suggested to 
play a role in the stretch-induced increase in muscle blood flow (62). 
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1.3.2 Skeletal muscle proteases 
Based on the biochemical mechanism of proteolysis, there are five families of 
proteases: serine-, threonine-, cysteine-, aspartate- and metalloproteases (63). The 
serine protease family is vast, with 245 described members, both intra- and 
extracellular. The most well-characterized members of the extracellular serine 
proteases are the digestive enzymes trypsin and chymotrypsin, the members of the 
coagulation cascade and neutrophil elastase (64). The threonine family consists of 35 
intracellular proteases including members of the proteasome, which is thought to play a 
role in muscle atrophy with unloading (38). The cysteine family of proteases has 163 
members including the cathepsin family, the calpain family and the caspase signaling 
cascade (64). There are also some extracellular proteases in the cysteine family but 
none has been reported in the context of skeletal muscle. Intracellular cysteine 
proteases in the skeletal muscle are members of the calpains, which have been 
associated with degradation of intracellular structural proteins after muscle damage 
(65). Calpains escaping to the extracellular milieu has also been suggested to play a 
part in degradation of IGF-binding proteins after muscle damage (66). Levels of the 
intracellular proteases calpain 1, 2 and 3 and cathepsin B and L have been reported to 
increase in human skeletal muscle with eccentric exercise (67). Pepsin and renin are 
extracellular proteases of the aspartate family but there are no reports on these 
proteases in skeletal muscle.  
Even though there are extracellular members of the serine and cysteine protease 
families, the most renowned and probably most important protease family for ECM 
remodeling is the MMP family. MMPs are involved in and are in many cases rate 
limiting for processes such as cell migration and the release of sequestered growth 
factors, in general and probably also in the skeletal muscle (68). 
 
1.4 MATRIX METALLOPROTEINASES 
1.4.1 Structure 
Matrix metalloproteinases (MMPs) are a family of zinc- and calcium-dependent 
enzymes consisting of 23 family members in humans. MMPs are grouped into five 
different classes according to their structure and substrate specificity; these are 
collagenases, gelatinases, stromelysins and membrane-type MMPs (MT-MMPs). 
Seventeen of the MMPs are secreted whereas there are six cell membrane-associated 
MMPs (MMPs 14–17 and 24–25) (69). 
All MMPs share a common domain structure: an N-terminal signal peptide that 
directs the enzymes to the secretory pathway, a prodomain with a conserved 
PRCGXPD sequence that confers the latency of the enzymes and a catalytic domain in 
which the catalytic zinc moiety is localized in the active site cleft. In addition, all but 
MMP-23 contain a hemopexin-like (HPX) domain linked to the catalytic domain 
through a hinge region. MT-MMPs have an additional domain, the transmembrane 
domain (70, 71). The various domains, modules and motifs of the MMPs are involved 
in interactions with other molecules, and hence affect or determine substrate specificity, 
cell and tissue localization and activation of MMPs. For instance, MMP-2 and MMP-9 
contain a module of three fibronectin II (FnII)-like inserts (72). These inserts can 
interact with elastin, types I, III, IV, V, X and XI collagens, as well as with gelatins. 
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This may facilitate the localization of these enzymes to connective tissue matrices. This 
interaction appears to be of importance for the degradation of macromolecules e.g. 
elastin, gelatin and collagens IV, V and XI, but does not influence the degradation of 
chromogenic substrates or other macromolecules (73). 
The best-characterized overall biological function of the MMP family is 
degradation of extracellular matrix proteins, and collectively, the MMPs can degrade 
all extracellular proteins (74). Such extracellular matrix remodeling occurs not only 
under physiological conditions such as bone remodeling, embryological development 
and the menstrual cycle, but also under numerous pathological conditions such as 
stroma remodeling and metastasis in cancer development, responses to ischemia-
reperfusion insults and inflammation (71, 75-80). MMPs not only create a migration 
path for migrating cells, but also release ECM-sequestered growth factors and 
cytokines (81). There are also reports providing evidence that MMP substrates also 
include non-ECM molecules ranging from growth factor binding proteins and receptors 
to cell surface adhesion molecules (71, 75-80). There are three MMP family members 
that have been recognized in a skeletal muscle context: MMP-2, MMP-9 and MMP-14. 
 
1.4.2 Regulatory factors 
MMPs, synthesized as prozymogens, are either secreted or membrane-bound and are 
subsequently processed and activated, enabling localized degradation of their substrates 
(73). Regulation of MMP activities is achieved at multiple levels: transcriptionally, 
translationally, by activation of the zymogen, and by inhibition of the active enzyme 
(74).  
The MMP-9 gene contains several regulatory cis elements. It contains a 
TATA box, an AP-1, an NF-KB and a PEA3-binding site (82). Increased 
transactivation through AP-1 or PEA3 is achieved largely through mitogen-activated 
protein kinase (MAPK)-mediated phosphorylation, but activated p38 kinases also 
increase the cellular amount of AP-1 protein indirectly by increasing transcription from 
the c-jun and c-fos promoters (72). Nuclear NF-KB levels are regulated by an 
inflammatory cytokine-activated pathway and, in particular, TNF-alpha is a well-
established inducer of MMP-9 expression in this fashion (83-85). The promoters of 
MMP-2 and MMP-14 do not contain a TATA box, and expectedly, transcription from 
these promoters starts at multiple sites. The ubiquitous Sp-1 family of transcription 
factors, which bind to a proximal GC box, mainly determines the gene expression of 
these MMPs (73). Consequently, expression of these MMPs is largely constitutive with 
no distinct inducibility by growth factors or cytokines (74). In addition, protein levels 
of MMPs are affected by posttranslatory mechanisms under certain circumstances. 
TGF-beta increases both MMP-2 and MMP-9 levels through an increase in mRNA 
half-life. In contrast, the pharmacological inhibitor of MMP, doxycycline, acts both as 
a chelating agent (see below) and by decreasing MMP mRNA stability (86, 87). 
Activation of the zymogen of MMPs is achieved by two mechanisms. 
One is through binding of regulatory molecules to allosteric sites and the other is 
proteolytic removal of the prodomain of the zymogen. Factors able to activate MMPs 
allosterically are organomercurials such as APMA, reactive oxygen species and 
detergents such as SDS. Interactions of this kind obviously occur mainly in vitro and 
are utilized in laboratory methods such as zymographic estimation of enzyme activity 
(see below) (73). There are also allosteric interactions of MMPs that have relevance in 
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in vivo conditions. Both pro-MMP-2 and pro-MMP-9 have been shown to become 
activated by mere interaction with gelatin, and more importantly, collagen IV (73, 88). 
A special case of allosteric interaction is binding of MMP-9 to neutrophil gelatinase-
associated lipocalin (NGAL) (89). NGAL is known to form a covalent heterodimer 
with proMMP-9. The full function of such binding is not known but the binding of 
MMP-9 to NGAL hinders binding of MMP-9 to its main endogenous inhibitor, TIMP-
1 (see below) and thus increases or prolongs its activity. NGAL was originally isolated 
from human neutrophils in a monomeric and a homodimeric form, and in addition, as 
an NGAL–MMP-9 complex (90). There are secretory granules in human neutrophils 
containing NGAL with no MMP-9 and vice versa, but there are also granules 
containing preformed heterodimers of NGAL-MMP-9 (91). NGAL appears to be 
expressed exclusively by neutrophils and the gene is expressed in myelocytes and 
metamyelocytes in the bone marrow and then stored in secretory granules until 
activation (92, 93). The level of NGAL is often used as a marker of inflammation and 
leukocyte activation and has recently been accepted as a biomarker for acute kidney 
injury(94).  
A large number of proteases are involved in proteolytic activation of proMMPs. 
Both MMP-2 and MMP-9 have been shown to be activated in vivo, not only by serine 
proteinases such as chymase and trypsin, but also by circulating plasmin. The 
activation of MMP-2 mainly occurs at the cell surface via a cascade mediated by 
MMP-14. First, cell surface MMP-14 binds a TIMP-2 molecule, forming a receptor 
complex for MMP-2. In this complex, TIMP-2 functions as an adaptor molecule, 
mediating the binding of MMP-2 to MMP-14 by hydrophobic interactions between the 
carboxy terminal domain of TIMP-2 and the hemopexin-like domain of MMP-2. In this 
manner, MMP-2 is concentrated at the cell surface and brought into proximity of 
MMP-14 for proteolytic activation (73, 88). 
 
1.4.3 Endogenous inhibitors 
TIMPs are the major natural inhibitors of MMPs. In addition, other proteins with MMP 
inhibitory activity have been discovered, such as the procollagen C-terminal proteinase 
enhancer and tissue factor pathway inhibitor 2. However, these proteins have modest 
inhibitory capacity against MMPs compared with TIMPs (69, 95). 
Until now, four different human TIMPs have been discovered: TIMP-1, -
2, -3 and -4. TIMPs are glycoproteins with molecular weights of 20–30 kDa, which 
function as important physiological regulators of the activity of MMPs. TIMP 
molecules form high-affinity, noncovalent inhibitory complexes with MMPs in a 1:1 
enzyme:inhibitor ratio. TIMPs have different specificities for different MMPs. For 
instance, TIMP-1 is the only TIMP that binds with high affinity to MMP-9. TIMP-1 
binds modestly with MMP-2, whereas TIMP-2 interacts with high affinity with MMP-
2. The relationship between MMP-2 and TIMP-2 is not a mere inhibitory one, as 
TIMP-2 is highly involved in the activation of MMP-2 as mentioned above. TIMP-1 is 
an inducible protein, as opposed to TIMP-2, which has a constitutive expression pattern 
(69, 88, 96). 
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1.4.4 Targets 
Several hundred target proteins have been identified for both MMP-2 and MMP-9. 
However, most of these substrates are either theoretical and based on protein sequences 
or were established under optimal in vitro conditions. Methodological advances such as 
mass-spectrometric identification of proteins after 2D gel electrophoresis and ultra-high 
pressure liquid chromatography have resulted in the verification and identification of 
several new substrates under in vivo conditions (97, 98).  
MMP-2 and MMP-9 both degrade the major component of the basal lamina, 
collagen IV. Such degradation is of crucial importance for successful extravasation of 
circulating cells and for the migration of cells between the compartments of the tissue 
(99, 100). Consequently, blockade of MMP activity suppresses various forms of 
cellular movement and has been shown to abolish skeletal muscle angiogenesis during 
exercise in the rat (48). In vitro studies have also revealed diminished migration of 
myoblasts after blockade of MMP-9 and upregulation of gene expression and activity 
during migration (101-107). In addition, MMP-2 and MMP-9 both digest other major 
components of the ECM such as collagen III, laminin and fibronectin (64, 72, 91). The 
degradation products of these ECM components are not always mere debris; several 
fragments of structural proteins have biological activity after proteolytic release. The 
best-characterized active fragment is endostatin, which is a cleavage product of 
collagen XVIII. It was discovered as an antiangiogenic agent about a decade ago by 
Folkman et al. and has been tested as an antiangiogenic agent because of its inhibitory 
effects on endothelial cell proliferation and migration (108, 109). Endostatin can be 
generated by several proteases, including MMP-9, and during the past decade, several 
other protein cleavage products have been shown to play potential roles in angiogenic 
processes. Two such cleavage products are tumstatin and angiostatin, which are 
generated by MMP-9 from collagen IV and fibrin, respectively (100, 109-113). 
Regulation of signaling molecules by MMPs is not limited to cleavage 
products. In one of the first reports on MMP-9 in cancer progression, it was illustrated 
that MMP-9 can release preformed VEGF-A from the ECM and thereby initiate an 
angiogenic response (114). Furthermore, the bioavailability of another growth factor 
relevant to skeletal muscle plasticity, IGF-1, has been shown to be influenced by 
MMP-9 degradation of IGF-binding proteins (115, 116). 
 
1.4.5 Possible physiological roles for MMP in human skeletal muscle  
It is clear that the extracellular proteolytic activity of MMPs is of importance for many 
biological processes. Based on cell and cancer model studies and to some extent on 
physiological models, MMP-2 and MMP-9 have been established as key players in 
processes ranging from degradation of structural components during cell migration to 
regulation and generation of growth factors. Many of these processes are probably of 
major importance for skeletal muscle remodeling and adaptation to exercise, and it is 
known that MMP-activity is important for skeletal muscle angiogenesis in the rat, that 
MMP-9 is upregulated in the human tendon after exercise, and that circulating levels of 
MMP-9 increase after downhill running. However, little is known about these enzymes 
in the skeletal muscle of humans and how physiological stimuli such as exercise and 
exercise training affect their expression and activity. 
  9 
2 AIMS 
The overall aim of this thesis was to characterize expression and activity of MMPs in 
humans undergoing exercise and to investigate the underlying stimuli.  
 
The specific aims were to further elucidate: 
1. Skeletal muscle MMP activation in response to a single bout of exercise and exercise 
training with regard to gene expression and enzyme activity. 
2. Exchange of factors associated with MMP activity between exercising leg and the 
circulation during exercise. 
3. Possible cellular sources of MMP in skeletal muscle tissue and blood.  
4. The effects of restricted leg blood flow, and the thereby reduced oxygen delivery to 
the exercising leg on skeletal muscle and circulating levels of MMP  
5. The effects of the myokine interleukin-6 on MMP levels in skeletal muscle and in 
the circulation.  
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3 METHODS AND METHODOLOGICAL 
CONSIDERATIONS 
3.1 EXPERIMENTAL DESIGN 
3.1.1 Subjects 
In total 32 healthy men participated in study I-IV.  
In study I and III, 10 subjects participated. The mean (range) age, height and weight of 
the subjects were 25 (18-37), 180 (170-190) cm and 77 (58-82) kg. 
In study II, 10 subjects were included. Their mean (range) age, height, and weight were 
24 (20–27) yr, 181 (173–190) cm, and 75 (63–90) kg.  
In study IV, 12 healthy human male subjects were inlcuded. The mean (range) age of 
the subjects was 27 (21-34). 
All subjects included in the studies were healthy and did not take any medication. All 
subjects gave informed consent to participate and the local ethics committee approved 
the studies.  
 
3.1.2 Experimental settings 
3.1.2.1 Exercise protocol study I and III 
Ten subjects performed two-legged upright cycling. The average VO2max in the 
participating subjects was: 51 (43-64) ml kg/min. The subjects cycled for the first 20 
min at workload equivalent to 50% of VO2max (125 ±20 W), after which they cycled a 
further 40 min at a higher workload equivalent to 65% of VO2max (165 ± 30 W). 
Finally, the subjects were instructed to cycle at the highest tolerable workload (175 ± 
50 W) that could be sustained for 5 min. Teflon catheter were inserted in the femoral 
artery and into the ibsilateral femoral vein, at the level of the inguinal ligament. Blood 
samples were drawn at rest, at 20, 40, 60 min of exercise, and 120 min after exercise 
and used to calculate the arterio-venous differences. Muscle biopsies were performed 
from the vastus lateralis muscle of one leg at rest, at 65 min of exercise and 120 min 
after exercise. 
3.1.2.2 Exercise protocol study II 
Eleven subjects performed one-legged exercise four times per week, over a five-week 
period. The average VO2max in the participating subjects was 51 (40–66) ml kg/min. 
The subject first performed one-legged exercised with restricted leg blood flow for 45 
min, after which the subject performed similar amount of exercise with non-restricted 
blood flow using the other leg. Blood-flow restriction was achieved by exposing the 
exercising leg to 50 mm Hg supraatmospheric pressure in an exercise model first 
described by Eiken (117). This has been shown to reduce blood-flow during exercise 
with 15-20% (118).  The subjects were instructed to exercise at the highest tolerable 
workload for 45 min, taking into account that they must complete the full 45-min 
session. Compared with the workload in the first week, the average workload increased 
by 30 % ± 22 in week 2, 52 % ± 39 in week 3 and 84 % ± 7 % in week 4. Muscle 
biopsies were performed from the vastus lateralis muscle of both legs before and 120 
min after the first exercise bout. Post-training samples were performed after five weeks 
at rest and 120 min after the last exercise bout; the resting was performed 24 h after the 
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previous exercise session. A further resting biopsy (24 h after the latest exercise bout) 
was performed from each leg 10 days after the start of training period. 
3.1.2.3 Experimental protocol study IV 
This study was a collaborative study with Bente Klarlund Pedersen and collaborators at 
Rigshospitalet in Copenhagen (Denmark). At the experimental day, subjects arrived at 
0800 h following an overnight fast. The femoral artery of one limb was cannulated and 
used for the infusion. Subjects (n=6) were infused with recombinant human Il-6 (rhIl-6) 
for 3-h at a rate of 5 µg/h, in a volume of 25 ml/h. The rhIl-6 was administered in 20% 
albumin. Control subjects (n=6) were infused with 20% albumin for 3-h. Plasma Il-6 
concentrations (approximately 100 ng/L) and the Il-6 expression in abdominal fat have 
been previously reported (Keller et al 2003). 
 
3.2 MUSCLE SAMPLES 
3.2.1 Biopsies 
In all studies, biopsies were performed from the vastus lateralis muscle, using the 
percutaneous needle biopsy technique (Bergström, 1962). All muscle biopsy samples 
were frozen in liquid nitrogen within 10-15 s and stored at –80°C until further analysis. 
 
3.2.2 Arteriovenous differences 
Teflon catheters were inserted into the femoral vein and artery at the level of the 
inguinal ligament. Blood samples were drawn simultaneously from the femoral artery 
and the ipsilateral femoral vein at rest before exercise, during, and 120 min after the 
end of exercise. The arteriovenous concentration differences were calculated from the 
measured arterial and venous concentrations. 
 
3.2.3 In vitro experiments 
3.2.3.1 Monocytes 
The human THP-1 acute monocytic leukaemia cell line (THP-1) was cultured in RPMI 
+ Glutamax (Invitrogen) supplemented with; 10% foetal calf sera (FCS) (Invitrogen), 
pencillin streptomycin (1%, Invitrogen), 1mM sodium pyruvate and 0.05mM b-
mercaptoethanol. The cells were maintained at 37°C with 5% CO2 and seeded in 24-
well plates with a cell density of 1x10^6/mL. The cells were stimulated for either one 
or three hours with Il-6 concentration 0 (ctrl), 1, 10 or 50 ng/mL. Each experiment was 
conducted with three replicates. 
3.2.3.2 Macrophages 
THP-1 –cells seeded in 24-well plates as described above were treated with 5% phorbol 
12-myristate 13-acetate (PMA) for 24 hours to differentiate to a macrophage 
phenotype. Cells were washed three times prior to any further experiments in order to 
evade non-adhering cells and debris. Subsequently cells cells were stimulated for either 
one or three hours with Il-6 concentration 0 (ctrl), 1, 10 or 50ng/mL. Each experiment 
was conducted with three replicates. 
3.2.3.3 Myoblasts 
The satellite cells were extracted from fresh muscle: Immediately following the biopsy 
procedure approximately 100 mg of muscle tissue was placed in sterile PBS containing 
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1% of streptomycin in 4° C over night. The sample was incubated in 5 ml 0.25 % 
Trypsin EDTA in 37° C, 5% CO2 with gentle agitation for 20 minutes.  Undigested 
tissue was allowed to settle for 5 minutes and the supernatant was collected in 5 ml 
Dulbecco’s Modified Eagle’s Medium (DMEM-F12), with 20 % fetal calf serum and 1 
% Penicillin Streptomycin. The cells were cultured until reaching 60% confluence. 
Cells were seeded in 6-well plates and were kept proliferating prior to experiment. The 
cells were stimulated for one or three hours with 0, 1, 10 or 50ng/mL Il-6 in serum free 
DMEM media. Each experiment was conducted with three replicates. After stimulation 
the cells were taken for RNA extraction. 
3.2.3.4 Myotubes 
Myoblasts were differentiated to myotubes by serum starvation for >72 hours prior to 
the experiment. The cells were stimulated for one or three hours with 0, 1, 10 or 
50ng/mL Il-6 in serum free DMEM media. Each experiment was conducted with three 
replicates. After stimulation the cells were taken for RNA extraction. 
3.2.3.5 Human umbilical chord endothelial cells 
Primary cultures of HUVEC were obtained from fresh umbilical cords. The umbilical 
vein was incubated with 0.1% dispase for 30 min. After isolation cells were kept in 
DMEM. Cells were seeded in 24-well plates. The cells were stimulated for one, two or 
four hours with Il-6 concentration 0 (ctrl), 10 or 150ng/mL in 20% FCS DMEM. Each 
experiment was conducted with three replicates. After stimulation the cells were taken 
for RNA extraction. 
 
3.3 LABORATORY METHODS 
3.3.1 Laser capture and microdissection  
Cryosections (8 µm thick) were freshly cut, placed on uncoated glass slides, and 
immediately immersed in cold acetone for 3 min followed by transfer to a –80°C 
freezer, where they were stored for a maximum of 1 wk. To prevent RNA degradation 
during histological staining, RNAase inhibitor was added to all sterile PBS solutions 
(50 U/100 µl; SUPERaseIn, Ambion). The laser capture and microdissection was 
performed using the P.A.L.M. system (Carl Zeiss microimaging). From muscle tissue 
sections, larger areas of muscle tissue covering all cell types and individual muscle 
fibers were dissected from the same section. After capturing the sum of 100 muscle 
fibers and subsequently an area of tissue of the same size as the fibers from each 
section, the caps were inserted into 0.5-ml microcentrifuge tubes filled with 50 !l of 
extraction buffer (PicoPure RNA isolation kit, Arcturus Engineering). 
 
3.3.2 Enzyme-linked immunosorbent assay 
In study I skeletal muscle protein levels of VEGF-A and endostatin was analyzed with 
ELISA. Part of the skeletal muscle biopsy (40 µl buffer/mg wet muscle) was 
homogenized in ice-cold buffer containing 0.1 M potassium phosphate (pH 7.7), 0.05% 
BSA, 20 µg/ml leupeptin, 50 µg/ml aprotinin and 40 µg/ml PMSF. The homogenate 
was rotated for 60 min at 4 °C and centrifuged at 15.000 g for 15 min at 6 °C. Two 
hundred microlitres of the 1:5 diluted supernatant was used to quantify protein utilising 
sandwich ELISA (Quantikine R&D Systems, USA). All techniques and materials in 
this analysis were used according to manufacturers’ protocols. Optical density was 
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quantified on a micro plate-reader *Quant (Bio- Tek® Instruments Inc., USA). All 
samples were assayed in duplicate. 
Circulating VEGF, endostatin, MMP-9 and NGAL levels were quantified by sandwich 
ELISA (VEGF-A Quantikine R&D Systems, Endostatin Cytimmune Science Inc) 
using similar procedures as those described for tissue VEGF-A. All techniques and 
materials used in this analysis were used in according to the manufacturer’s protocol. 
Plasma elastase was quantified by competetive ELISA (KA0163, Abnova) according to 
manufacturer’s protocol. 
 
3.3.3 Zymography 
Zymography supplies were purchased from Invitrogen (Carlsbad, CA). MMP-2, pro-
MMP-9, and active MMP-9 distribution was determined from muscle biopsy 
homogenate using the samne procuder as described for ELISA. Subsequently gelatin 
substrate zymograms were prepared using precast 10% SDS-polyacrylamide gels 
contain- ing 1 mg/ml of gelatin. Equal volumes of experimental media samples (25 ug) 
were diluted into 2"x Tris-glycine SDS sample buffer and electrophoretically separated 
under nonreducing conditions. Proteins were incubated in renaturing buffer 
(Invitrogen) for 30 min at room temperature. The gels were incubated overnight at 
37°C in developing buffer (Invitrogen). After 1 h staining with Coomassie blue and 
destaining for 2 days with 10% acetic acid and 40% methanol in water, gelatinase 
activity was evident by clear bands against a dark blue background. Quantification of 
the bands was performed using digital camera Fujifilm LAS-1000 or Canon 40d and 
densiometry software Fujifilm Image gauge version 3.46. 
 
3.3.4 Immunohistochemistry 
Frozen biopsy samples were embedded in OCT (Tissue-Tek, Sakura Finetek) and kept 
frozen at 80°C until further analysis. Cross sections (5 !m) of biopsy samples were cut 
at 21°C, placed on glass slides. Sections for MMP-9 staining were put in 4% 
formaldehyde, and sections for MMP-2 staining were put in 99% ethanol for 10 min for 
fixation in room temperature. After washing in PBS for 3 " 5 min, the sections were 
incubated with PBS containing 3% BSA and 0.1% Triton X-100 (Dako) for 30 min at 
room temperature. A rabbit anti-human MMP-9 antibody (Sigma-Aldrich) diluted 
1:500 in PBS with 1% BSA and 0.3% Triton X-100 was applied to the sections and 
incubated at 37°C for 60 min, and subsequently the sections were incubated overnight 
at 4°C with a rabbit anti-human MMP-2 antibody (Sigma-Aldrich) diluted 1:250 in 
PBS with 1% BSA. Following washing, the sections were incubated for 60 min with a 
cyanine-3- conjugated secondary antibody donkey anti-rabbit (Jackson Immu- 
noResearch) diluted 1:500 in 1% BSA at 37°C for 60 min. The sections were mounted 
with Vectashield (Vector Laboratories). Double staining was achieved by coincubation 
of the primary antibody together with sarcolemmal marker, a mouse anti-human 
caveolin-3 antibody (Santa Cruz Biotechnology) diluted 1:500 or an endothelial cell 
marker mouse anti-human CD31 (Dako) diluted 1:100. A FITC- conjugated donkey 
anti-mouse secondary antibody (Jackson Immuno Research) diluted 1:500 was added 
in the double-staining protocols. As a negative control, the primary antibodies were 
excluded from the protocol. 
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3.3.5 Reverse transcribed real-time PCR 
In studies I-III total RNA was prepared by the acid phenol method (Chomczynski and 
Sacchi, 1987) and quantified spectrophotometrically by absorbance at 260 nm. The 
integrity of the total RNA was determined by 1% agarose gel electrophoresis. Two 
micrograms of RNA was reverse transcribed by Superscript reverse transcriptase (Life 
Technologies, Stockholm, Sweden) using random hexamer primers (Roche Diagnostics 
GmbH, Mannheim, Germany) in a total volume of 20 µl. 
RNA isolated by LCM was kept in extraction buffer (PicoPure RNA isolation kit, 
Arcturus Engineering). After incubation in 42°C for 30 min, the extraction buffer was 
collected by a brief spin (800 g for 2 min), the caps were removed, and the 
microcentrifuge tubes were stored in 80°C. Total RNA was extracted from the cell 
lysate using the PicoPure RNA isolation kit according to the manufacturer’s protocol. 
The isolated RNA was stored frozen in 80°C until use. Isolated RNA was reverse 
transcribed by Superscript reverse transcriptase (Life Technologies, Solna, Sweden) 
using random hexamer primers (Roche Diagnostics) in a total volume of 30 ul. 
In studies I-III, mRNA was detected on an ABI-PRISM 7700 Sequence Detector 
(Perkin- Elmer Applied Biosystems Inc, Foster City, CA, USA). Oligonucleotide 
primers and TaqMan probes was ordered as gene assay on demand (Perkin-Elmer 
Applied Biosystems Inc.).  As an endogenous control to correct for potential variations 
in RNA loading 18S rRNA was selected in study I-II (18S 4310893E, Perkin-Elmer 
Applied Biosystems Inc.) and GAPDH (Hs99999905-m1) was selected in study IV. All 
reactions were performed in 96-well MicroAmp Optical plates, using the ABI-PRISM 
7700 Sequence Detector (Perkin-Elmer Applied Biosystems Inc.). For every gene, all 
samples were amplified simultaneously in duplicate in one assay run. The threshold 
cycle was determined for both the experimental gene and the endogenous control gene, 
and was used to calculate the relative expression. 
 
3.4 STATISTICS 
The data were analyzed using logarithmic-transformed ratios for mRNA, and 
logarithmic-transformed densiometric values for zymographies. In the analysis of 
plasma and serum concetrations over time concentrations was corrected for 
hemoconcentration by normalisation to plasma albumin. For analysis of arteriovenous 
differecenes raw data was used. 
A one-way analysis of variance (ANOVA) for repeated measures was used to 
evaluate the effect of time on mRNA and protein expression. Post hoc analysis used 
planned comparisons to locate the points of interaction. A two-way ANOVA for 
repeated measures evaluated the effects of time and localization (artery or vein) in 
arteriovenous differences and to evaluate the effects of training (before, 10 days, and 
five weeks) in the two exercise conditions on basal mRNA and protein content. 
Planned comparison was used (i.e. post hoc-test) to locate differences corresponding to 
significant interactions or when no interaction was found to locate differences 
corresponding to significant main effects in the ANOVA models. MMP-activity was 
analyzed by a nonparametric method for comparison of multiple dependent samples 
(Friedman ANOVA, Kendall coefficient of concordance and Wilcoxon matched pair 
test). Cell culture gene-expression was analyzed with unpaired students t-test. Data are 
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presented as mean and SEM unless otherwise stated. For all tests, P <0.05 was 
considered significant. 
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4 RESULTS AND DISCUSSION 
4.1 SKELETAL MUSCLE MMP 
4.1.1 Skeletal muscle MMP activity and expression 
In study I, skeletal muscle MMP-2 mRNA and gelatinolytic activity were estimated 
before, immediately after, and 2 hours after a single bout of cycling exercise. MMP-2 
levels remained stable at all three times. Study II supports the findings from study I in 
that no change in MMP-2 mRNA or activity was detected after a single bout of 
exercise, but both mRNA and enzyme activity increased after 10 days of exercise 
training (i.e., four exercise bouts). Koskinen et al reported that MMP-2 mRNA and 
enzyme activity increased in rats 2 days after a bout of downhill running (119, 120). 
The notion of an exercise-induced increase in MMP-2 in the skeletal muscle was 
confirmed by Carmeli et al, who showed increased expression of MMP-2 in rats 
performing exercise bouts at high intensity (70% of VO2max) but not at moderate 
intensity (50% of VO2max) for 2 weeks (121-123). 
Heinemeier et al also investigated MMP-2 in rat skeletal muscle and compared the 
response to concentric, eccentric, and isometric physical activity. In that study, skeletal 
muscle MMP-2 increased 24 hours after 4 days of repeated bouts of exercise. (124). 
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Hellsten et al estimated MMP-2 after 90 minutes of passive stretch and, consistent with 
the findings in this thesis, did not detect any changes in the MMP-2 transcription or 
enzyme activity (125). Based on the consistent findings of concomitant increases in 
MMP-2 mRNA and activity in this thesis and in other studies, it appears that MMP-2 is 
upregulated after repeated bouts of exercise, presumably regulated mainly at the 
transcriptional level.  
 
 
In contrast to MMP-2, MMP-9 mRNA and enzyme activity increased 
after 60 minutes of cycling exercise in study I. The protein levels of MMP-9 increased 
significantly by about twofold immediately after exercise, whereas the increase in 
MMP-9 mRNA reached significance 2 hours after exercise. In study II, skeletal muscle 
MMP-9 levels increased after a single bout of exercise, both at the protein and mRNA 
levels. In study II, samples were obtained before and 2 hours after the exercise bout, 
and steady-state levels of MMP-9 were assessed by analyzing mRNA and zymography 
at least 48 hours after the last training session after 10 days and 5 weeks of exercise 
training. After 10 days of exercise, MMP-9 mRNA levels increased and remained 
elevated after 5 weeks of exercise training. By contrast, the MMP-9 protein levels did 
not increase significantly after 10 days or 5 weeks of exercise training. In resting 
muscle (i.e., in the preexercise biopsies) in both studies I and II, the MMP-9 mRNA 
levels were low, and these values were reflected in threshold cycle values > 35 in all 
but two subjects; MMP-9 mRNA was undetectable in two subjects despite high 
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concentrations of cDNA. In all other samples, MMP-9 was detectable albeit at 
relatively high cycle threshold values in many cases. This led to a high variance in the 
increase with time and prohibited the possibility of investigating interactions between 
the two exercise conditions using two-way ANOVA in study II; instead, a Wilcoxon 
matched-pair test was used. 
 
The difference between mRNA and activity in MMP-9 immediately after 
exercise in study I probably reflects activation of preformed MMP-9. By contrast, in 
study II, the basal expression of MMP-9 mRNA was increased throughout the training 
program but without any evidence of increased activity in resting muscle. Taken 
together, the current observations indicate that MMP-9 activity is not regulated only at 
the translational level. 
In studies I and II, TIMP-1 and MMP-14 mRNA increased with the 
increase in MMP-2 (i.e., with training), which is consistent with previous reports in the 
rat (48, 124). MMP-14 is a membrane-associated MMP and in terms of skeletal muscle 
expression, it appears to be upregulated in parallel with MMP-2 in injury models, 
during mechanical overload, and after exercise (126, 127). Consitent with the results in 
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this thesis, TIMP-1 has been shown to increase with exercise training in rat skeletal 
muscle, and has also been reported to increase in plasma immediately and up to two 
weeks after after eccentric work in human subjects (124, 128, 129). 
 
 
4.1.2 MMP localization 
In study II, immunohistochemistry and laser capture microdissection were used to 
identify the localization and cellular source of MMP-2 in skeletal muscle. Such 
information can provide indirect insight into the regulating stimuli and possible targets 
of a factor of interest. In the immunohistochemical investigation, sections were double 
stained with antibodies directed against MMP-2, CD31 (an endothelial cell marker), 
and caveolin 3, which was used as a sarcolemmal marker. Sections were also 
counterstained with DAPI. A generalized distribution pattern was seen in the 
immunohistochemistry: clear positive areas between all muscle fibers and staining 
around the CD31+ endothelial cells. The localization of MMP-2 in the muscle tissue is 
consistent with previous findings, although no study had reported that MMP-2 is 
expressed in adult muscle fibers (130, 131). Satellite cells also express MMP-2, but 
studies on SaC MMP-2 expression are usually in vitro studies (47, 101, 102, 106). 
As seen in immunohistochemistry scattered MMP-2-positive areas appear 
within the muscle fibers. Because no double staining of the protein synthesis machinery 
such as ribosomes, Golgi or exocyme proteins was performed, it is not possible to 
conclude whether this reflects actual intracellular MMP-2 or a staining artifact. 
Interestingly, recent studies show that there are intracellular forms of MMP-2. 
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Intracellular MMP-2 is thought to become activated by skeletal muscle atrophy and 
digestion of both intracellular and extracellular proteins, which reduce muscle mass and 
the thickness of the ECM(132-136). These findings suggest that an intracellular MMP-
2 is present in muscle fibers. 
 
Laser capture microdissection of muscle fibers with subsequent analysis 
of MMP-2 mRNA was used to further address the question of whether MMP-2 is 
expressed in skeletal muscle. This technique was used to first inspect tissue sections 
under a microscope and then, using a focused laser beam, to cut out areas of interest for 
further analysis. Skeletal muscle fibers were cut and captured, and the MMP-2 mRNA 
was analyzed. The purpose was to determine whether the skeletal muscle fibers express 
MMP-2 and hence contribute to the MMP-2 deposited throughout the ECM of the 
muscle. Milkiewicz et al used the LCM technique to isolate skeletal muscle endothelial 
cells in the rat and reported that endothelial MMP-2 gene expression increased in vivo 
and in vitro with muscle overload (137, 138). The data from the LCM in study II add to 
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this observation by showing that the muscle fiber is another likely source of MMP-2. 
Samples from before and after 10 days of exercise training were analyzed, albeit only 
from three subjects because of the limited biopsy specimens available and because 
optimization of the experimental protocol consumed vast amounts of material. Despite 
this limitation, the mRNA level of MMP-2 normalized to 18S was higher after 10 days 
of exercise in all three subjects. This is the same pattern of expression as in the muscle 
as a whole, and this observation supports the idea that the muscle fiber contributes to 
the overall increase in MMP-2 after exercise training. 
 
Immunohistochemical staining in study II suggested an even distribution 
of MMP-9 throughout the ECM of resting skeletal muscle. This was also reported by 
Zimowska et al in a rat study and by Singh et al in human masseter muscle (47, 131). 
These findings and the current observations contrast with a report that MMP-9 
expression is restricted to atrophic fibers in patients with myositis (139). No MMP-9 
mRNA was detected in laser-dissected muscle fibers or in endothelial cells 
(unpublished data) in resting or in exercised muscle. This likely reflects that the MMP-
9 mRNA level acquired with laser dissection is below the detection limit for the real-
time PCR measurement. There are methodological difficulties associated with protein 
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quantification by immunohistochemistry. However, MMP-9 was detectable throughout 
the ECM of the muscle despite the low abundance of mRNA at rest, suggesting that in 
skeletal muscle there is a low turnover of MMP-9, with only minor translation and 
degradation of the MMP-9 deposited in the ECM. 
In study IV, basal levels of MMP-9 mRNA were observed in both 
myoblasts and myotubes. The measured levels were low, and thus were similar to those 
noted in skeletal muscle as a whole at rest in studies I and II. Myoblasts express MMP-
9 during migration and differentiation in vitro (101, 103-107). Less is known about 
expression of MMP-9 in vivo. Zimowska et al suggested that MMP-9-positive 
mononuclear cells localize around destroyed muscle fibers in a rat muscle injury model 
where they are activated to become satellite cells, although this was not verified by 
control staining or dissection (47). In muscle from patients with myositis of various 
etiologies, mononuclear cells expressing MMP-9 comprise macrophages and 
neutrophils (130, 131). This observation agrees with the general view that MMP-9 is 
associated mainly with invading immune cells under inflammatory conditions (92). 
 
4.1.3 Possible regulation of skeletal muscle MMP 
The expression patterns of MMP-2, MMP-9, MMP-14, and TIMP-1 in studies I and II 
indicate that these factors are regulated by different stimuli or through dissimilar 
mechanisms during exercise. This is consistent with differences in the promoter regions 
of these molecules (140). For example, the MMP-2 gene lacks a TATA box and is 
expressed constituently in most tissues; few studies have reported upregulation of the 
MMP-2 gene by growth factors and cytokines (140). There is little or no basal 
expression of MMP-9, but its promoter region contains a variety of response elements 
that are sensitive to a wide range of growth factors and cytokines (140). 
As argued above, physical exercise is a complex process involving 
several factors, such as reduced tissue oxygen level, increased muscle tension, and 
increased shear stress and wall tension in blood vessels, that could each affect the 
expression levels of MMP-2 and MMP-9 in skeletal muscle (141-143). The purpose of 
the experimental design in study II was to identify the factors responsible for the 
activation of MMPs. Several aspects of the exercise stimulus can differ between 
exercise with and without restricted blood flow. This is reflected in differences in the 
activation of canonical pathways and gene expression and, ultimately, in differences in 
skeletal muscle adaptation. Exercise with restricted blood flow reduces oxygen tension 
in skeletal muscle, increases glycogen depletion, and causes metabolic perturbation 
(e.g., increased lactate level and decreased ATP–PCr concentration) (118, 144). 
Another difference is the greater total activation of muscle fibers during exercise with 
restricted blood flow compared with unrestricted blood flow. It is very likely that 
reduction in the total blood flow over the leg also decreases capillary flow velocity and 
hence shear stress in the microvascular endothelial cells (118, 144). The importance of 
these differences is demonstrated by a more robust angiogenic response, greater 
mitochondrial biogenesis, and a larger increase in oxidative enzyme activities and 
number of capillaries after 4 weeks of exercise training with restricted blood flow 
compared with exercise with unrestricted blood flow (118, 144-146). 
In study II, MMP-2 levels increased after 10 days of exercise training 
without any difference between the two exercise conditions. These observations do not 
support the idea that oxygen tension or metabolic perturbation is critical to the 
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regulation of the expression or activation of MMP-2. By contrast, the stimuli that are 
similar in the two exercise conditions are muscle mechanical load and stretch. The 
expression of MMPs in skeletal muscle endothelial cells is affected by mechanical 
stretch (137, 138, 147), and MMP-2 expression in muscle tendon is increased by 
mechanical loading (124, 148). Consistent with the observations in study II, repeated 
bouts, but not a single bout, of passive stretching of the leg increases skeletal muscle 
MMP-2 (125, 149). Taken together, these findings suggest that mechanical load or 
stretch is the stimulus responsible for upregulation of skeletal muscle MMP-2 
expression. Eccentric exercise induces a greater mechanical load compared with 
concentric work (150), and the report by Heinemeier et al showed a trend to a larger 
increase in MMP-2 following eccentric exercise. Even though the MMP-2 gene is 
expressed constitutively in many tissues, a few transcription factors, such as SP1, have 
been reported to increase its gene expression (151). Interestingly, mRNA stability, 
DNA binding, and nuclear translocation of SP1 increase after repeated bouts but not 
after a single bout of electrical stimulation of C2C12 myotubes (152, 153). This is 
consistent with the increase in MMP-2 expression after exercise training but not after a 
single bout of exercise in studies I and II, and after repeated passive stretch reported by 
Hoier et al (149). 
Based on the MMP-9 gene promoter sequence and as observed in in vitro 
studies, there is a range of plausible mechanisms to explain the prompt increase in 
MMP-9 gene expression observed in studies I and II. In general, MMP-9 expression 
and activity are associated with inflammation and cytokine signaling, often through 
MAPK pathways such as p38 and ERK (92, 154-156). Several of the MAPK-pathways 
are activated by exercise in human skeletal muscle (157-159), and several stimuli such 
as metabolic perturbation and mechanical stretch can activate these pathways in animal 
and in vitro models (85, 160, 161).  
TNF-α is one inflammatory cytokine shown to induce both gene 
expression and activity of MMP-9 in cultured myoblasts and in skeletal muscle of mice 
infused with TNF-α (83, 85, 106). Even though TNF-α is upregulated markedly in 
traumatically injured skeletal muscle, there is little evidence for an increase in TNF-α 
in the skeletal muscle by exercise (162-166). It has also been suggested that an 
inflammatory response to the biopsy procedure might induce MMP-9 in the skeletal 
muscle. To determine whether this could explain the findings in studies I and II, MMP-
9 mRNA was measured in two muscle biopsies taken from the same leg at 2-hour 
intervals in the absence of exercise in eight subjects. The MMP-9 mRNA level did not 
change with time (P = 0.3, data not shown). 
Importantly, oxygen tension and other factors related to exercise with 
restricted blood flow cannot be excluded as the underlying reasons for MMP-9 because 
the mean increase in MMP-9 was much higher in the leg exercised with restricted 
blood flow than in the leg exercised without blood flow restriction. The nonsignificant 
difference between the two exercise conditions could be related to lack of statistical 
power. Earlier reports have shown that MMP-9 is induced in ischemic muscles and that 
the promoter region of MMP-9 is responsive to many cellular signals and growth 
factors associated with metabolic stress (140, 162, 167). This is the case both for acute 
experimental limb ischemia and for steady-state levels in muscles of patients with 
peripheral artery disease (141). However, there is a large difference in the magnitude of 
perturbation in ischemic models versus physical exercise. Although oxygen tension in 
the muscle decreases during exercise and even more so in exercise with restricted blood 
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flow, the oxygen tension during femoral artery ligation or severe peripheral artery 
disease reaches tissue-damaging levels, which is evident by invasion of inflammatory 
cells and the appearance of necrotic muscle fibers. Therefore, the increased levels of 
MMP-9 under ischemic conditions do not necessarily reflect the reduced oxygen 
tension per se but might be the consequence of tissue damage. In study I, MMP-9 
activity did not increase significantly before the appearance of a significant increase in 
mRNA levels, indicating activation of preformed MMP-9. 
Nitric oxide has received attention as a potential MMP-activating factor 
in the skeletal muscle (83, 168, 169). Both MMP-2 and MMP-9 can become activated 
through allosteric interaction with nitric oxide. Nitric oxide is a free radical and, as 
such, it has biologically relevant effects beyond the activation of guanylyl cyclase. It is 
well established that skeletal muscle produces nitric oxide at low rates at rest and at 
higher rates during muscle contraction (170, 171). Both endothelial cells and muscle 
fibers can release nitric oxide; the main stimuli for nitric oxide release are shear stress 
in endothelial cells and mechanical stretch in muscle fibers. As argued above, shear 
stress tends to be lower during restricted blood flow compared with unrestricted blood 
flow. Previous studies using an experimental model similar to that used in this work 
have shown that the plasma concentration of nitrate, the main metabolite of nitric oxide 
in humans (172), increases during exercise with restricted blood flow but not during 
exercise without restricted blood flow (118). If nitric oxide was a critical factor for the 
observed exercise-induced activation of MMP, the activity patterns of MMP-2 and 
MMP-9 should also be similar and, presumably, higher following exercise with 
restricted blood flow. 
TIMP-1 upregulation occurs primarily at the transcriptional level and 
involves AP-1, SP1, NF-κB, and CRE transcription factors, providing regulation that is 
similar to that of MMP-9. Several studies have reported skeletal muscle upregulation of 
TIMP-1 expression without expression of MMP-9 (58, 124, 173). This indicates that 
TIMP-1 and MMP-9 are not regulated by identical stimuli even though they are often 
induced in parallel. The overall effect of an increase in the activating factor MMP-14 
and the inhibiting factor TIMP-1 as observed in study II remains to be elucidated. 
Finally, the results of a rat skeletal muscle injury model suggested that 
both MMP-9 and MMP-2 can become activated through interaction with proteases 
released from circulating leukocytes (142). Even though the invasion of leukocytes into 
the skeletal muscle after exercise is thought to be a minor event, one might speculate 
that proteases released from circulating cells contribute to the activation of skeletal 
muscle MMP-9 after exercise. 
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4.2 CIRCULATING MMP 
In study III, the femoral arteriovenous differences for MMP-9, collagen IV, NGAL, 
and elastase were calculated in the leg before, during, and after 60 minutes of cycling 
exercise.  
In study III, the circulating levels of MMP-9 increased above the 
preexercise levels after 30 minutes of cycling exercise, remained elevated during the 
exercise bout, and decreased to preexercise levels 2 hours after the end of the exercise 
bout. This increase was not accompanied by any release or uptake of MMP-9 over the 
exercising leg. 
Earlier studies demonstrated an increase in MMP-9 concentration in the 
circulation after muscle-damaging strenuous exercise. Studies using eccentric exercise 
and an exhaustive incremental step test reported increased serum MMP-9 concentration 
immediately following the end of exercise (128, 174). The data from study III do not 
support the assumption that circulating MMP-9 is derived from skeletal muscle or 
tendons because no MMP-9 appeared to have been released from the exercising leg. 
These findings support the idea that the circulating MMP-9 noted during and after an 
exercise bout comes from a source other than the skeletal muscle or tendon. One 
possible link between the exercising muscle and circulating MMP-9 is skeletal muscle-
derived cytokines. 
Based on the rapid kinetics of the elevation in MMP-9 level after 30 minutes of 
exercise, one might presume that the increase in circulating MMP-9 level resulted from 
the release of preformed MMP-9 from secretory granules rather than from a 
transcriptional mechanism. Neutrophils carry preformed MMP-9 in secretory vesicles, 
which can be released quickly under inflammatory conditions such as activation by 
lipopolysaccharide and cytokines or by adhesion to integrins (175). Neutrophil 
degranulation causes the release of several factors other than MMP-9, such as 
neutrophil gelatinase-associated lipocalin and elastase. In contrast to MMP-9, elastase 
is released exclusively from neutrophils and can therefore be used as a marker of 
neutrophil degranulation (89, 90). Study III showed an uptake of NGAL over the 
exercising leg but neither circulating NGAL nor elastase levels changed with exercise. 
The concordance with regard to stable NGAL and elastase levels in study III contradict 
the idea that neutrophils are a likely source of the observed increase in MMP-9 level 
during and after exercise. 
 
4.2.1 Possible mechanism underlying the release and the cellular source of 
circulating MMP 
Contracting skeletal muscle expresses a number of cytokines and releases them into the 
circulation; these cytokines may have both paracrine and endocrine effects. Il-6 has 
attracted much attention because many studies have reported exercise-induced 
increases in circulating Il-6 levels and within the exercising muscle. Circulating Il-6 
may increase up to 100-fold following exercise and as much as 8000-fold after 
ultraendurance-type exercise (165, 176). Study IV tested whether Il-6 causes an 
increase in circulating MMP-9 level by infusing recombinant Il-6 in healthy subjects 
until the Il-6 level in the circulation was similar to that reported with exercise. After 3 
hours of Il-6 infusion, serum MMP-9 level was almost 5-fold higher than the 
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preinfusion level; in control subjects, MMP-9 levels were unchanged. After cessation 
of the Il-6 infusion, MMP-9 level decreased and reached the preinfusion level 5 hours 
after the end of the infusion. The peak serum MMP-9 level during the Il-6 infusion was 
similar to the levels observed in study III and in previous reports on the response of 
circulating MMP-9 during exercise (128, 129, 174, 177, 178). 
 
 
Previous reports on Il-6 infusion in healthy subjects have reported 
increased circulating neutrophil numbers (84, 89, 91, 92, 175, 179). However, in study 
IV, NGAL and elastase levels remained unchanged during and after Il-6 infusion, 
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indicating that there was no degranulation of neutrophils. Maybe more importantly, 
these data open for Il-6 as a possible agent behind the increase in circulating MMP-9 
seen during exercise in study III.  An additional observation was an uptake of NGAL 
over the exercising leg in study III. This uptake was however, based on the stable levels 
of NGAL overall, quantitatively small. Interestingly, in study I, NGAL–MMP-9 
complexes were detectable in the zymograms from the skeletal muscle in six subjects, 
and there was a slight, although nonsignificant, increase in skeletal muscle NGAL level 
in four of these six subjects. Based in these findings, one might speculate that, during 
exercise, there is a slight uptake of unbound NGAL from the circulation to the tissue 
where it binds to active MMP-9. 
Another possible source of circulating MMP-9 are monocytes: 
Monocytes express the two Il-6 receptors: Il-6R and GP-130. Stimulation by Il-6 has 
several effects on monocytes in vitro (180-183). In the human monocyte cell-line THP-
1, we detected an increase in MMP-9 mRNA after Il-6 treatment, suggesting that 
circulating monocytes are a possible source of MMP-9. 
Many other cell types located in the peripheral tissue can express and 
release MMP-9 if stimulated appropriately (83, 106, 184). To test whether cells present 
in skeletal muscle that are known to express MMP-9 were involved in the observed 
increase in MMP-9 level following Il-6 stimulation, we stimulated cells with Il-6 for 
one and three hours. This experimental design also allowed us to study whether Il-6 is 
involved in the increased 
MMP-9 level observed within the skeletal muscle tissue during and after exercise. 
The panel of cells selected included the major cellular components of the skeletal 
muscle: myoblasts, myotubes, and endothelial cells (HUVECs). In addition, THP-1 
cells differentiated to a macrophage phenotype were included because of their known 
expression of MMP-9 and suggested role in skeletal muscle remodelling (185-187). 
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Cells were stimulated with Il-6 in vitro for 1 or 3 hours. Myoblasts 
showed a low but detectable level of MMP-9 mRNA, but we detected no change after 
stimulation with Il-6. In differentiated myotubes, MMP-9 level was barely detectable in 
RT-PCR, and this was unaltered by Il-6. The difference in the basal expression of 
MMP-9 in myoblasts versus myotubes agrees with previous data showing that the 
detectable level of MMP-9 in myoblasts decreases following differentiation (101, 106). 
In the studies of this thesis, a low or undetectable level of MMP-9 was noted in resting 
skeletal muscle, but MMP-9 level increased quickly following an exercise bout (studies 
I and II). Hence, the present data do not support the idea that Il-6 stimulation is 
responsible for the exercise-induced gene expression of MMP-9 in skeletal muscle. 
In HUVECs, we detected MMP-9 in unstimulated cells, but as in 
myoblasts, 1 or 3 hours of Il-6 treatment had no effect on MMP-9 level. This finding 
contrasts with the findings in human cerebral endothelial cells, in which Il-6 increases 
the expression and release of MMP-9 (184). In that study, MMP-9 level was measured 
after 24 hours but not after short-term stimulation, which might explain the differences 
between our results. Taken together, the data from that study and the present data do 
not support the idea that endothelial cells are the source of MMP-9 after short-term 
stimulation with Il-6. 
Macrophages have a high basal expression of MMP-9, but the expression 
was unaffected by stimulation with Il-6. Thus, the responses of monocytes and 
macrophages differ. Interestingly, studies at the cell level have suggested that MMP-9 
plays a pivotal role in the activation of monocytes and their differentiation into 
macrophages in peripheral tissues (180, 183, 188). MMP-9 degrades components of the 
ECM and basal lamina; such degradation is necessary for leukocyte invasion and 
migration (181, 189). Immunohistochemical studies in MDX mouse models and in 
human studies of myopathies have shown that invading macrophages secrete MMP-9 
(139, 190-192). 
Considering the lack of response to short-term Il-6 stimulation in the 
three cell types comprising most of the skeletal muscle cells, we propose that the 
cellular source of the serum MMP-9 observed during and after exercise is unlikely to 
be within the skeletal muscle tissue. This is further supported by a previous study that 
used Affymetrix to analyze gene expression in skeletal muscle biopsies from vastus 
lateralis obtained after an Il-6-infusion protocol similar to that used in the present study. 
This study detected no skeletal muscle MMP-9 gene expression after Il-6 infusion 
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(193). It does further contradict Il-6 as the mediator behind the activation of MMP-9 
seen in study I and II. 
 
4.3 POSSIBLE ROLES OF MMP 
The best characterized overall biological function of the MMP family is the 
degradation of ECM proteins; collectively, the MMPs can degrade all extracellular 
proteins. Type IV collagen is a key component of the basal lamina (194) and comprises 
a major substrate of MMP-9 (143). In study III, arteriovenous differences in collagen 
IV were measured over the exercising leg. An arteriovenous difference in collagen IV 
corresponding to its release from the exercising leg was noted after 30 minutes of 
exercise. The circulating level of collagen IV increased during exercise, suggesting that 
the release from the leg was robust, or alternatively that collagen IV is also released 
from other tissues during exercise. 
Collagen XVIII is another component of the basal lamina (195). 
Endostatin is a C-terminal cleavage product of collagen XVIII and was one of the first 
naturally occurring antiangiogenic factors described. Endostatin inhibits endothelial 
cell proliferation and migration in vitro and interferes with VEGF-A signaling, and has 
been tested as an antiangiogenic agent in several clinical trials (100, 109-111). The 
enzymatic cleavage of endostatin from collagen XVIII is a process mediated by several 
proteases, including MMP-9 (110, 113, 196). In study I, the femoral arteriovenous 
difference and skeletal muscle level of endostatin were analyzed to provide a marker of 
possible antiangiogenic processes occurring during exercise and as a possible MMP-9-
generated factor. Endostatin protein levels in the skeletal muscle did not change 
significantly at either time after exercise. Both arterial and venous levels of endostatin 
increased above the preexercise values at 17 and 57 minutes of exercise. There was also 
a significant turnover of endostatin over the exercising leg, with an uptake of endostatin 
at 17 minutes of exercise but a release of endostatin at 57 minutes of exercise. Arterial 
and venous endostatin levels returned to preexercise levels by 120 minutes after the end 
of exercise. 
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The increase in circulating endostatin level before any release could be 
detected over the exercising leg suggests that the endostatin is not derived from the 
exercising leg. The decline in endostatin 2 hours after exercise is consistent with recent 
reports from Suhr et al, who also reported a slight increase in endostatin level 
immediately after exercise and a fast decline after exercise (174). In clinical trials, the 
plasma half-life of administered endostatin was a few hours (197). Taken together, 
these data suggest that endostatin is released during but not after exercise; presumably, 
it is released from a tissue other than the exercising leg and then removed from the 
circulation quickly after the end of exercise. The alternating uptake and release of 
endostatin over the exercising leg in study I had no effect on skeletal muscle levels, 
indicating that this turnover was of minor significance. It is not known if the increase in 
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circulating endostatin during exercise is due to MMP-activity. Still, one may speculate 
that release of an anti-angiogenic factor such as endostatin during ECM-remodelling 
plays a role in hindering activation of endothelial cells in adjacent areas and remote 
organs in an endocrine fashion. 
VEGF-A is a growth factor that has been shown to be regulated 
posttranslationally by MMP-9 under certain circumstances; by sequestering ECM 
components, VEGF-A deposited in the ECM is made diffusible and is then released. 
This phenomenon was first described by Bergers et al in a model of pancreatic cancer 
and has since been reported in several other pathologies (111, 114, 198). In 
physiological contexts, such as exercise, the transcriptional regulation of VEGF-A is 
the most well-established mechanism, but studies have reported an increase in VEGF-A 
protein before any increase in VEGF-A mRNA (45, 46, 62, 198-200). Study I analyzed 
skeletal muscle content and exercising leg arteriovenous differences of VEGF-A. 
Skeletal muscle VEGF-A protein level was not significantly increased immediately 
after exercise but was significantly higher 120 minutes after exercise compared with 
preexercise levels. By contrast, VEGF-A mRNA level was significantly elevated 
immediately after exercise and remained elevated for 120 minutes after exercise. After 
17 minutes of exercise, there was a significant arteriovenous difference that 
corresponded to the release of VEGF-A from the exercising leg. At the end of the 
exercise bout, there were no detectable arteriovenous differences and no significant 
change in VEGF-A level compared with the preexercise level. By contrast, 120 minutes 
after the exercise bout, circulating VEGF-A level was lower than the preexercise levels 
in both the artery and the vein. 
 
The fact that collagen IV and VEGF-A were released from the exercising 
leg in studies III and I, together with the findings of an increase in active MMP-9 in the 
skeletal muscle immediately after exercise in studies I and II point to a possible 
connection: MMP-9 in the skeletal muscle during exercise cleaves collagen IV in the 
basal lamina of the muscle, which leads to a release of collagen IV and VEGF-A from 
the muscle. However, it is not possible to exclude a role of other collagen IV-degrading 
proteases, such as cathepsin B or MMP-3, in the collagen IV release during exercise. 
However, based on the known activation of skeletal muscle MMP-9 by exercise, 
MMP-9 is a plausible candidate. 
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5 FINAL REMARKS 
The skeletal muscle is an almost ideal model for studying the physiology and molecular 
biology of adaptive processes in humans: the skeletal muscle tissue is accessible 
percutaneously in large enough quantities for thorough analysis with minimal risk and 
discomfort for the donor. The skeletal muscle is a highly plastic organ with relatively 
well-characterized phenotypical and structural changes in response to stress such as 
physical exercise, changes that can be related to the molecular findings and 
phenomenology. Human physiology research plays an important part in understanding 
the processes and mechanisms that may reflect the pathophysiological changes 
occurring in cell and animal models. The study of human physiology may help 
elucidate the role of these mechanisms in the homeostasis of life. Even though research 
on human models is descriptive and has a lesser ability to isolate a stimulus or to knock 
down a mechanism of interest, human experimental models are essential for our 
understanding of both physiology and pathophysiology.  
Little is known of the role MMPs play in the adaptive processes within 
skeletal muscle. Increasing evidence points toward a role for the MMPs in skeletal 
muscle remodeling. For instance, a recent study in MMP-9-null mice reported 
decreased overall muscle mass and fiber-type shifts compared with wild-type mice 
(201). This thesis demonstrate that endurance type of exercise activate members of the 
MMP family in skeletal muscle and increase MMP-9 levels in the circulation. The 
thesis also provides insight of an endocrine effect of the myokine Il-6. The data also 
provide insight into one possible activating mechanism of the MMP family with 
physical exercise. It further suggest proteolytical processing of skeletal muscle ECM to 
occur during an exercise bout and that this processing possibly release preformed 
VEGF-A to the circulation. All together the current findings support involvement of 
MMPs in the adaptation to endurance exercise in humans. 
Further knowledge about the effects of exercise on the substrate panel of 
MMPs and characterization of the proteolytically processed fragments of both 
structural proteins and possibly growth factors in the skeletal muscle and in the 
circulation are important for elucidating the role MMPs play in muscle remodeling. 
Thorough studies using a morphological approach or in vitro experimentation in 
isolated mononuclear cells are needed to understand the importance of cell migration to 
skeletal muscle remodeling and to determine whether the MMPs are essential. 
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